Viraj Mehta's Biography

Viraj Mehta, Research Fellow, Indian Institute of Technology, Hyderabad

Viraj Mehta is a final-year Ph.D. student at IIT Hyderabad, India.He works at Regenerative Medicine and Stem cell Laboratory in the biomedical engineering department. He obtained his Bachelor's degree in mechanical engineering from NIT-Surat. After which he joined IIT Hyderabad as the most prestigious Prime Minister's Research Fellow (PMRF) in 2018. His thesis topic is related to the development of 3D printed tumor-on-a-chip for functional multi-drug testing. He was awarded the Gandhian Young Technological Innovation award (GYTI) in 2019 by the vice-president of India for developing a novel tumor-on-a-chip as a part of his Ph.D. work. In addition, he was also awarded the Research Excellence award in 2022 by IIT Hyderabad.

Towards Functional Precision Medicine: Microfluidic Platform For Combinatorial Drug Screening Using Stereolithography

Wednesday, 14 September 2022 at 14:00

Add to Calendar ▼2022-09-14 14:00:002022-09-14 15:00:00Europe/LondonTowards Functional Precision Medicine: Microfluidic Platform For Combinatorial Drug Screening Using Stereolithography3D-Models for Drug Testing: Organoids and Tissue Chips 2022 in SeattleSeattleSELECTBIOenquiries@selectbiosciences.com

3D printed resin based microfluidic fabrication has been gaining popularity for the past 10 years. Although there are several reports utilizing resin based techniques for micro fluidic tumor culture and drug screening, multi-drug-based 3D printed tumor models are still lacking. In this study, we report a novel microfluidic device for 3D culture of breast and oral tumor spheroids. Our device is capable of forming highly circular spheroids on flat bottom 3D printed microwells. Besides, the device can test various combinations of three anti-cancer drugs simultaneously. As the combination of drugs can reduce drug concentrations and are more effective than single drug therapies, we believe discovering potential drug combinations on patient-derived samples will aid in mitigating the side effects of chemotherapy. The tumor spheroids maintain excellent viability in the device for 120 h. We observe differential drug sensitivities among tested patient samples matching their diagnosis. In addition, we show that tumor spheroids can be taken out from the developed device for downstream analysis such as flow cytometry.

Add to Calendar ▼2022-09-13 00:00:002022-09-14 00:00:00Europe/London3D-Models for Drug Testing: Organoids and Tissue Chips 20223D-Models for Drug Testing: Organoids and Tissue Chips 2022 in SeattleSeattleSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors